The landscape of medical research is currently witnessing significant growth in cannabinoid clinical trials, with over 50 companies actively engaged in developing novel therapies. A recent report, ‘Cannabinoid Pipeline Insight 2025,’ from DelveInsight Business Research LLP highlights a robust pipeline of more than 55 cannabinoid-based drugs currently in various stages of clinical development. This momentum suggests a growing scientific interest in the potential therapeutic applications of compounds like cannabidiol (CBD) and tetrahydrocannabinol (THC) for a range of health conditions.
The Expanding Landscape of Cannabinoid Clinical Trials
The DelveInsight report indicates a dynamic environment where pharmaceutical companies are exploring cannabinoids for conditions spanning mental health disorders, neurodegenerative diseases, and chronic inflammation. This extensive pipeline involves key players such as Zynerba Pharmaceuticals, Incannex Healthcare, IGC Pharma, INC., SciSparc, Biopharmaceutical Research Company, and Innocan Pharma Corporation, among others.
Therapies currently undergoing investigation include:
- ZYN-002 (Zynerba Pharmaceuticals): In Phase III trials for Fragile X syndrome.
- IHL-675A (Incannex Healthcare): Under evaluation.
- IGC-AD1 (IGC Pharma, INC.): In Phase II for Alzheimer’s disease.
- SCI-110 (SciSparc): In Phase II for agitation, Alzheimer’s disease, Gilles de la Tourette’s syndrome, and sleep apnoea syndrome.
- BRC-002 (Biopharmaceutical Research Company): In Phase I for Complex Regional Pain Syndrome (CRPS).
- Cannabidiol-loaded LPT (Innocan Pharma Corporation): In preclinical stages for epilepsy and pain.
These diverse applications underscore the broad potential of cannabinoids, building on earlier insights into their pharmacological profiles, as previously reported by Hemp Gazette.
Recent Advancements in Cannabinoid Research
Several companies have announced significant progress in their cannabinoid research pipelines, contributing to the momentum in cannabinoid clinical trials:
- MIRA Pharmaceuticals (July 2025): Reported positive preclinical data for Mira-55, a proprietary non-psychotropic marijuana analog, reporting effects on pain comparable to morphine in an inflammatory pain model without causing local inflammation.
- InMed Pharmaceuticals (June 2025): Announced new preclinical data reporting that INM-901 reduced inflammation in ex vivo models of neuroinflammation, suggesting its potential for Alzheimer’s disease.
- Corbus Pharmaceuticals Holdings (March 2025): Initiated the dosing of the first subject in a Phase I trial for CRB-913, a cannabinoid type-1 (CB1) receptor inverse agonist drug, for the investigation of obesity.
- IGC Pharma, Inc. (January 2025): Named its ongoing Phase II trial for agitation in Alzheimer’s disease ‘CALMA’ (Calming Agitation in Alzheimer’s). In September 2024, IGC Pharma also announced data reinforcing IGC-AD1’s potential as a disease-modifying therapy for Alzheimer’s, reporting effects on tau tangles, spatial memory, and previously, amyloid plaque reduction.
- Biopharmaceutical Research Company (BRC) (December 2024): Received Orphan Drug Designation from the US Food and Drug Administration (FDA) for BRC-002 for Complex Regional Pain Syndrome (CRPS).
Understanding Cannabinoids and Their Therapeutic Potential
Cannabinoids are chemical compounds that interact with the body’s endocannabinoid system, a complex network involved in regulating pain perception, mood, appetite, and immune function. These compounds can be naturally derived from the cannabis plant (phytocannabinoids like THC and CBD), produced by the human body (endocannabinoids like anandamide), or created synthetically.
While THC is known for its psychoactive effects, CBD is recognised for its potential therapeutic benefits without causing intoxication. The FDA has approved CBD (Epidiolex) for certain rare forms of epilepsy, such as Lennox-Gastaut and Dravet syndromes. Research also suggests CBD may be associated with managing anxiety, inflammation, and neurodegenerative conditions. Research indicates that THC may assist in managing chronic pain, reducing chemotherapy-induced nausea and vomiting, and stimulating appetite in individuals with HIV/AIDS. Combinations of THC and CBD are also under investigation for conditions like multiple sclerosis and specific cancer-related pain.
Beyond these well-known compounds, other cannabinoids like cannabigerol (CBG) and cannabinol (CBN) are being studied for their potential in conditions such as glaucoma and insomnia. Synthetic cannabinoids, including FDA-approved medications like nabilone and dronabinol, offer standardised options for managing nausea and appetite loss.
The ongoing expansion of cannabinoid clinical trials underscores a concerted effort to explore these compounds as potential alternatives or complementary therapies in modern medicine, including for autoimmune disorders, post-traumatic stress disorder (PTSD), and opioid addiction.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
